J
Jelena Bila
Publications - 1
Citations - 167
Jelena Bila is an academic researcher. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 1, co-authored 1 publications receiving 57 citations.
Papers
More filters
Journal ArticleDOI
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label phase 3 trial
Sebastian Grosicki,Maryana Simonova,Ivan Spicka,Ludek Pour,Iryrna Kriachok,Maria Gavriatopoulou,Halyna Pylypenko,Holger W. Auner,Xavier Leleu,Vadim A Doronin,Ganna Usenko,Nizar J. Bahlis,Roman Hájek,Reuben Benjamin,Tuphan Kanti Dolai,Dinesh Kumar Sinha,Christopher P. Venner,Mamta Garg,Mercedes Gironella,Artur Jurczyszyn,Pawel Robak,Monica Galli,Craig T. Wallington-Beddoe,Atanas Radinoff,Galina Salogub,Don A. Stevens,Supratik Basu,Anna M. Liberati,Hang Quach,Vesselina Goranova-Marinova,Jelena Bila,Eirini Katodritou,Hanna Oliynyk,Sybiryna Korenkova,Jeevan Kumar,Sundar Jagannath,P. Moreau,Moshe Yair Levy,Darrell White,Moshe E. Gatt,Thierry Facon,Maria V. Mateos,Michele Cavo,Donna E. Reece,Larry D. Anderson,Jean Richard Saint-Martin,Jacqueline Jeha,Anita A. Joshi,Yi Chai,Lingling Li,Vishnuvardhan Peddagali,Melina Arazy,Jatin P. Shah,Sharon Shacham,Michael G. Kauffman,Meletios A. Dimopoulos,Paul G. Richardson,Sosana Delimpasi +57 more
TL;DR: This phase 3, randomised, open-label trial aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortzomib and dex amethas one in patients with previously treated multiple myeloma.